Our study revealed that the TRIM3/TLR3 axis mediates TBK1/IRF3 pathway activation and drives IFN-β secretion, conferring antiproliferative effects against NSCLC. This evidence concerns the gene TRIM3 and non-small cell lung carcinoma.